Frexalimab (CD40L antagonist)
Sanofi / ImmuNext
What it is
A second-generation anti-CD40L monoclonal antibody in the FABULINUS phase-2b trial for children, adolescents and adults (ages 6-35) with newly diagnosed T1D. It aims to preserve C-peptide without lymphocyte depletion. The trial is listed as active, not recruiting (enrolment complete), but no T1D efficacy result is published yet.
Editorial review: .
Most recent recorded citation date: 2026-07-14. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Delay of onset: No published T1D efficacy result yet; the phase-2b FABULINUS trial uses C-peptide preservation after diagnosis, not onset delay, as its core test.[1]
- Important harms and treatment burden
- Safety: The appeal is immune modulation without lymphocyte depletion, but CD40L blockade has class-history safety questions and T1D safety is still being established.[2]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Durability is unknown; the trial record is described as including a 52-week blinded extension and optional open-label extension to study longer-term effects.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 25 × 30 + 25 × 20 + 45 × 20 + 25 × 15 + 10 × 15 = 2675; divide by total weight 100. Unrounded weighted result: 26.75.
No published T1D efficacy result yet; the phase-2b FABULINUS trial uses C-peptide preservation after diagnosis, not onset delay, as its core test.[1]
Durability is unknown; the trial record is described as including a 52-week blinded extension and optional open-label extension to study longer-term effects.[1]
The appeal is immune modulation without lymphocyte depletion, but CD40L blockade has class-history safety questions and T1D safety is still being established.[2]
Current T1D program is recent-onset stage 3 only; no stage-1/2 prevention data yet. The trial has since added a pediatric cohort (Part C, ages 6-11), broadening the population though not the stage.[1]
Investigational biologic; no regulatory approval for T1D or any routine diabetes access.[1]
Editor’s take
Frexalimab is a frontier bet: mechanistically attractive and serious enough to have a large Sanofi phase-2b trial, but still pre-result in T1D. It belongs in the map because CD40/CD40L costimulation is one of the clearest next immunotherapy axes after anti-CD3, CTLA4-Ig and JAK inhibition.
The full picture
What is being tested
Frexalimab is described as a CD40L antagonist; CD40L is part of a costimulation pathway involved in activating T cells, B cells and innate immune cells. FABULINUS is testing whether modulating that pathway in recent-onset T1D preserves the body's own insulin secretion.1
Who is in the trial
FABULINUS has grown since it opened. As of the registry update of 29 June 2026 (live-checked 27 August 2026) the trial lists actual n=197 participants aged 6 to 35 — the trial added a pediatric cohort (Part C, ages 6-11) alongside the original adult and adolescent groups. The two groups are judged on slightly different clocks: Part C has a 26-week C-peptide primary endpoint, the older cohorts a 52-week one. That widens who frexalimab is being tested in, but not when — everyone enrolled is newly diagnosed, so this is still a stage-3 recent-onset study, not a prevention study in people who have not yet developed diabetes.1
Evidence status
The trial is now active, not recruiting — enrolment is complete and participants are being followed. That is a milestone in logistics, not in evidence: there is still no published T1D efficacy result. Primary completion is estimated for April 2027, with study completion out in October 2030.1
The value of this record remains pipeline coverage: FABULINUS is large enough and mechanistically distinct enough that leaving it out would make the prevention/immunotherapy landscape look older than it is.
Coming soon
ETA · Phase-2b fully enrolled (active, not recruiting); primary completion estimated April 2027
- →FABULINUS phase-2b C-peptide readout (active, not recruiting; ages 6-35, n=197) · primary completion estimated April 2027
Sources
- [1]FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) · Trial registry · 2026-07-14 — Sanofi phase 2b; active, not recruiting as of last update 29 June 2026 (live-checked 27 August 2026); actual n=197; ages 6-35 (pediatric Part C covers 6-11); primary completion estimated 28 April 2027, study completion 29 October 2030. No results posted.
National Library of Medicine. FABULINUS: Frexalimab in recent-onset type 1 diabetes. ClinicalTrials.gov NCT06111586.
- [2]A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design · Peer-reviewed study · 2026-05-01 — Diabetes, Obesity and Metabolism design paper; DOI verified through search/Crossref during this pass.